Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (KITE) (H-38468)
Description
Content
A Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of Kte-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (Kite Pharma KTE-C19-104) (KITE)
Age Requirement: 2-21 years
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.
NCT#/ClinicalTrials.gov ID:02625480
Contact
Phone 1: 832–824–1798
IRB: H-38468
Status:
Active
Created:
